Jak2: normal function and role in hematopoietic disorders

被引：114

作者：

Ihle, James N. ^{[1
]}

Gilliland, D. Gary

机构：

[1] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA

[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol & Oncol,Howard Hughes Med Inst, Boston, MA 02115 USA

来源：

CURRENT OPINION IN GENETICS & DEVELOPMENT | 2007年 / 17卷 / 01期

关键词：

D O I：

10.1016/j.gde.2006.12.009

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Janus kinase 2 (Jak2) associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. Kinase activity is regulated by a series of interactions beginning with the requirement to bind to specific domains in receptors, suppression of activation by the pseudokinase domain, and the requirement for phosphorylation within the activation loop. Recent studies have implicated de-regulation of Jak2 kinase activity by chromosomal translocations in hematopoietic tumors and mutations within the pseudokinase domain in a spectrum of myeloproliferative diseases.

引用

页码：8 / 14

页数：7

共 36 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2] Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders [J].

Bellanne-Chantelot, Christine ;

Chaumarel, Isabelle ;

Labopin, Myriarn ;

Bellanger, Florence ;

Barbu, Veronique ;

De Toma, Claudia ;

Delhommeau, Frangois ;

Casadevall, Nicole ;

Vainchenker, William ;

Thomas, Gilles ;

Najman, Albert .

BLOOD, 2006, 108 (01) :346-352

[3] Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog [J].

Boggon, TJ ;

Li, YQ ;

Manley, PW ;

Eck, MJ .

BLOOD, 2005, 106 (03) :996-1002

[4] The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene [J].

Bousquet, M ;

Quelen, C ;

De Mas, V ;

Duchayne, E ;

Roquefeuil, B ;

Delsol, G ;

Laurent, G ;

Dastugue, N ;

Brousset, P .

ONCOGENE, 2005, 24 (48) :7248-7252

[5] The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera [J].

Cario, H ;

Goerttler, PS ;

Steimle, C ;

Levine, RL ;

Pahl, HL .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (05) :800-801

[6]

Carron C, 2000, BLOOD, V95, P3891

[7] Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 [J].

Funakoshi-Tago, Megumi ;

Pelletier, Stephane ;

Matsuda, Tadashi ;

Parganas, Evan ;

Ihle, James N. .

EMBO JOURNAL, 2006, 25 (20) :4763-4772

[8] A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia [J].

Griesinger, F ;

Hennig, H ;

Hillmer, F ;

Podleschny, M ;

Steffens, R ;

Pies, A ;

Wörmann, B ;

Haase, D ;

Bohlander, SK .

GENES CHROMOSOMES & CANCER, 2005, 44 (03) :329-333

[9] ACTIVATION OF A DROSOPHILA-JANUS-KINASE (JAK) CAUSES HEMATOPOIETIC NEOPLASIA AND DEVELOPMENTAL DEFECTS [J].

HARRISON, DA ;

BINARI, R ;

NAHREINI, TS ;

GILMAN, M ;

PERRIMON, N .

EMBO JOURNAL, 1995, 14 (12) :2857-2865

[10] CYTOKINE RECEPTOR SIGNALING [J].

IHLE, JN .

NATURE, 1995, 377 (6550) :591-594

← 1 2 3 4 →